Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology.

Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group.

Wien Klin Wochenschr. 2019 May;131(9-10):233-236. doi: 10.1007/s00508-019-1468-7. Epub 2019 Mar 18.

PMID:
30887224
2.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
3.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499
4.

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.

Ann Oncol. 2015 Feb;26(2):313-20. doi: 10.1093/annonc/mdu544. Epub 2014 Nov 17.

PMID:
25403582
5.

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.

Krzemieniecki K, Sevelda P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J, Trojan A, Szabo Z, Bendall K, Maenpaa J.

Support Care Cancer. 2014 Mar;22(3):667-77. doi: 10.1007/s00520-013-2021-2. Epub 2013 Oct 24.

6.

Impact of conization type on the resected cone volume: results of a retrospective multi-center study.

Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A, Polterauer S.

Arch Gynecol Obstet. 2013 Nov;288(5):1081-6. doi: 10.1007/s00404-013-2873-1. Epub 2013 May 7.

PMID:
23649464
7.

Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.

Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO).

Wien Klin Wochenschr. 2012 Jun;124(11-12):412-8. doi: 10.1007/s00508-012-0185-2. Epub 2012 Jun 28. Erratum in: Wien Klin Wochenschr. 2012 Sep;124(17-18):669. Singer, Christian [added].

PMID:
22739650
8.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.

J Clin Oncol. 2012 Mar 1;30(7):722-8. doi: 10.1200/JCO.2011.36.8993. Epub 2012 Jan 23.

PMID:
22271481
9.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.

10.

Validation of the S classification of sentinel lymph node and microanatomic location of sentinel lymph node metastases to predict additional lymph node involvement and overall survival in breast cancer patients.

Fink AM, Wondratsch H, Lass H, Janauer M, Sevelda P, Salzer H, Jurecka W, Ulrich W, Chott A, Steiner A.

Ann Surg Oncol. 2011 Jun;18(6):1691-7. doi: 10.1245/s10434-010-1545-7. Epub 2011 Jan 20.

PMID:
21249455
11.

Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.

Petru E, Reinthaller A, Angleitner-Boubenizek L, Schauer C, Zeimet A, Dirschlmayer W, Medl M, Stummvoll W, Sevelda P, Marth C.

Wien Klin Wochenschr. 2010 Nov;122(21-22):649-52. doi: 10.1007/s00508-010-1483-1. Epub 2010 Nov 15.

PMID:
21072604
12.

Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens.

Meinke AL, Senn BM, Visram Z, Henics TZ, Minh DB, Schüler W, Neubauer C, Gelbmann D, Noiges B, Sinzinger J, Hanner M, Dewasthaly S, Lundberg U, Hordnes K, Masoud H, Sevelda P, von Gabain A, Nagy E.

Vaccine. 2010 Oct 8;28(43):6997-7008. doi: 10.1016/j.vaccine.2010.08.041. Epub 2010 Aug 21.

PMID:
20732466
13.

Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology.

Marth C, Hiebl S, Oberaigner W, Winter R, Leodolter S, Sevelda P.

Int J Gynecol Cancer. 2009 Jan;19(1):94-102. doi: 10.1111/IGC.0b013e31819915cb.

PMID:
19258949
14.

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.

Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG; Austrian Fulvestrant Registry.

Breast Cancer Res Treat. 2009 May;115(2):373-80. doi: 10.1007/s10549-008-0132-0. Epub 2008 Jul 26.

PMID:
18661231
15.

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Apr 1;14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.

16.

Self-reported prostate cancer screening in Austria.

Vutuc C, Waldhoer T, Sevelda P, Micksche M, Haidinger G.

J Med Screen. 2006;13(3):148-51.

PMID:
17007656
17.

Investigation of 208 consecutive cases of cervical cone biopsies with regard to indication, negative samples and quality control.

Weigl G, Pokieser W, Schuller B, Weigert M, Ulrich W, Sevelda P, Breitenecker G.

Acta Cytol. 2006 Mar-Apr;50(2):185-90.

PMID:
16610687
18.

Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.

Baur M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H, Dittrich C.

Cancer Invest. 2006 Feb;24(1):22-7.

PMID:
16466988
19.

Impact of haemoglobin levels during adjuvant chemotherapy on the survival of patients with primary breast cancer.

Peters-Engl C, Cassik P, Schmidt I, Denison U, Medl M, Pokieser W, Sevelda P.

Acta Oncol. 2005;44(2):129-33.

PMID:
15788291
20.

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.

Baur M, Schernhammer E, Gneist M, Sevelda P, Speiser P, Hudec M, Dittrich Ch.

Br J Cancer. 2005 Mar 28;92(6):1019-25.

21.

Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy.

Denison U, Baumann J, Peters-Engl C, Samonigg H, Krippl P, Lang A, Obermair A, Wagner H, Sevelda P.

Breast Cancer Res Treat. 2003 Jun;79(3):347-53.

PMID:
12846419
22.

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.

Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A; Austrian Ovarian Cancer Study Group.

Eur J Cancer. 2003 May;39(8):1129-40. Erratum in: Eur J Cancer. 2004 Mar;40(4):627.

PMID:
12736113
23.

[Early experience with the advanced breast biopsy instrumentation system in a multicentre study].

Kwasny W, Tausch C, Haid A, Stierer M, Konstantiniuk P, Wayand U, Sevelda P.

Gynakol Geburtshilfliche Rundsch. 2002;42(4):212-6. German.

PMID:
12373025
24.

Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer.

Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, Agstner I, Seifert M, Sevelda P, Jakesz R.

Clin Breast Cancer. 2002 Apr;3(1):65-72.

PMID:
12020397
25.

Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study.

Peters-Engl C, Medl M, Denison U, Sevelda P, Leodolter S, Petru E.

Anticancer Res. 2001 Sep-Oct;21(5):3701-6.

PMID:
11848547
26.

Lunar phases and survival of breast cancer patients--a statistical analysis of 3,757 cases.

Peters-Engl C, Frank W, Kerschbaum F, Denison U, Medl M, Sevelda P.

Breast Cancer Res Treat. 2001 Nov;70(2):131-5.

PMID:
11768603
27.

[Second-Line Therapy of Ovarian Carcinoma]

Sevelda P.

Onkologie. 2000 Dec;23(6):593-596.

PMID:
11441268
28.
29.

Prognostic influence of delays between exploratory and definitive laparotomy in the treatment of malignant ovarian tumors.

Lehner R, Szabo S, Goharkhy N, Jirecek S, Tringler B, Sevelda P.

Arch Gynecol Obstet. 2001 Mar;265(1):36-9.

PMID:
11327092
30.

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjövall K, Timmerman D, Vandewalle J, Van Gramberen M, Tropé CG.

Lancet. 2001 Jan 20;357(9251):176-82.

PMID:
11213094
31.

First report of lymphatic mapping with isosulfan blue dye and sentinel node biopsy in cervical cancer.

Medl M, Peters-Engl C, Schütz P, Vesely M, Sevelda P.

Anticancer Res. 2000 Mar-Apr;20(2B):1133-4.

PMID:
10810409
32.

Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer.

Obermair A, Petru E, Windbichler G, Peters-Engl C, Graf AH, Stummvoll W, Kaider A, Kurschel S, Kölbl H, Sevelda P.

Oncol Rep. 2000 May-Jun;7(3):639-44.

PMID:
10767382
33.

[Guidelines for treatment of breast carcinoma by the Gynecological Oncology Working Group. Gynecological Oncology Working Group].

Concin H, Grünberger W, Kubista E, Menzel C, Pickel H, Reiner A, Seitz W, Sevelda P, Staudach A, Widschwendter M, Wolf G.

Gynakol Geburtshilfliche Rundsch. 1999;39(4):226-9. German. No abstract available.

PMID:
10629389
34.
35.

[Therapy studies of the Austrian Breast Cancer Group (ABC)].

Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Haider K, Mlineritsch B, Schmid M, Tausch C, Reiner G, Renner K, Stierer M, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Sevelda P, Dadak C, Haid A, Scholz R, Lenzhofer P, Steindorfer P, Berger A, Mischinger HJ.

Zentralbl Chir. 1998;123 Suppl 5:28-32. German.

PMID:
10063568
36.

TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.

Peters-Engl C, Buxbaum P, Ogris E, Sevelda P, Medl M.

Anticancer Res. 1998 Nov-Dec;18(6B):4635-9.

PMID:
9891532
37.

Influence of delayed staging laparotomy after laparoscopic removal of ovarian masses later found malignant.

Lehner R, Wenzl R, Heinzl H, Husslein P, Sevelda P.

Obstet Gynecol. 1998 Dec;92(6):967-71.

PMID:
9840559
38.
39.

[Hormones and cancer: risk-benefit].

Sevelda P, Salzer H.

Gynakol Geburtshilfliche Rundsch. 1998;38(2):61-3. Review. German.

PMID:
9815519
40.

Psammocarcinoma of the peritoneum diagnosed during operative laparoscopy.

Lehner R, Jaindl M, Wenzl R, Jirecek SG, Stengg K, Sevelda P.

Acta Obstet Gynecol Scand. 1998 Sep;77(8):870-1. No abstract available.

PMID:
9776605
41.
42.

The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review.

Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G.

Cancer. 1998 Aug 15;83(4):726-31.

PMID:
9708937
43.

[Guidelines for the management of simple ovarian cysts. A consensus report by AGO and AGE by request of OGGG. Austrian Society of Gynecology and Obstetrics].

Fabsits M, Fuith L, Keckstein G, Lang P, Lahousen M, Leodolter S, Reinthaller A, Rudelsdorfer B, Sevelda P, Staudach A, Stummvoll W, Winter R.

Gynakol Geburtshilfliche Rundsch. 1998;38(1):40. Review. German. No abstract available.

PMID:
9658714
44.

Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group.

Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M, Stierer M, Kolb R, Steger G.

Eur J Cancer. 1998 Jan;34(1):66-70.

PMID:
9624239
45.

Unsuspected primary tubal carcinoma during operative laparoscopy.

Wenzl R, Lehner R, Dräger M, Jirecek S, Gamper C, Sevelda P.

Gynecol Oncol. 1998 Mar;68(3):240-3. Review.

PMID:
9570973
46.

Color-coded and spectral Doppler flow in breast carcinomas--relationship with the tumor microvasculature.

Peters-Engl C, Medl M, Mirau M, Wanner C, Bilgi S, Sevelda P, Obermair A.

Breast Cancer Res Treat. 1998 Jan;47(1):83-9.

PMID:
9493979
47.

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

Kurz Ch, Marth Ch, Windbichler G, Lahousen M, Medl M, Vavra N, Sevelda P.

Gynecol Oncol. 1997 Jun;65(3):461-6.

PMID:
9190976
48.

[Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods].

Knappitsch G, Gruböck K, Salzer H, Kaider A, Kurz C, Vavra N, Speiser P, Sevelda P.

Gynakol Geburtshilfliche Rundsch. 1997;37(4):221-6. German.

PMID:
9609931
49.

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.

Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R.

Anticancer Res. 1997 Jan-Feb;17(1B):613-9.

PMID:
9066588
50.

Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.

Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P.

Gynecol Oncol. 1997 Jan;64(1):109-13.

PMID:
8995557

Supplemental Content

Loading ...
Support Center